Mark Rothera, Chief Commercial Officer at PTC THERAPEUTICS, INC. (PTCT), bought 2,000 shares at $6.23 ($12K) on 2016-03-03, disclosed to the SEC on 2016-03-07.
Open-market purchase of $12k PTCT by Chief Commercial Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| Filing → |
| PTCT | SELL | 2015-03-13 | $23K | — | Filing → |
| PTCT | SELL | 2015-02-25 | $2.4M | — | Filing → |
| PTCT | SELL | 2015-01-22 | $180K | — | Filing → |